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Resumo 
 
Artrite Reumatóide (AR) é uma doença crónica, inflamatória autoimune que afeta 
principalmente as articulações periféricas como as mãos e os pés, cuja causa é ainda 
ainda desconhecida. Esta doença tem uma incidência de cerca de 1% na população 
mundial, com maior prevalência no sexo feminino. As principais queixas por parte dos 
doentes são as articulações inchadas e dolorosas, rigidez matinal e fadiga. Para além 
destas queixas, esta doença é caracterizada a nível radiológico pela presença de 
erosões ósseas e destruição articular. Atualmente não existe um cura para esta 
doença, no entanto existem diversos tratamentos para melhor os sintomas e diminuir a 
progressão da AR: anti-inflamatórios não esteróides, corticosteróides, 
imunossupressores e mais recentemente drogas antirreumáticas biológicas, sendo 
estes últimos o tratamento mais inovador e melhorando significativamente a qualidade 
de vida destes doentes. Em doentes com artrite reumatóide ocorre infiltração do 
espaço sinovial entre as articulações por células do sistema autoimune que induzem a 
proliferação e ativação excessiva dos osteoclastos, que são as células responsáveis 
pela reabsorção óssea. Embora não sejam totalmente conhecidos os mecanismos que 
levam a este fenómeno, doentes com AR têm elevada reabsorção óssea que não é 
compensada pela formação óssea, devido a um comprometimento na proliferação e 
função dos osteoblastos, células responsáveis pela formação óssea. Ocorre assim um 
desequilíbrio que leva à perda de mineral óssea, sendo que muitos destes doentes 
sofrem de osteoporose secundária à inflamação. Ao nível dos osteoblastos, a via de 
sinalização Wnt controla a proliferação, ativação e funcionalidade destas células. Esta 
via pode ser inibida por diferentes proteínas, sendo as mais conhecidas DKK1, DKK2, 
SFRP1, SOST e WIF1. Segundo o que está descrito, a expressão dos inibidores da 
via de sinalização Wnt é induzida por fatores inflamatórios presentes nas membranas 
sinoviais de doentes com artrite reumatoide. Assim, a nossa hipótese é que a 
expressão destes inibidores está aumentada no osso de doentes com AR, o que leva 
a uma inibição dos osteoblastos.  
Para isso, doentes com diagnóstico de AR segundo os critérios ACR/EULAR 
revistos em 2010 submetidos a artroplastia total da anca entre 2007 e 2014 no Serviço 
de Ortopedia do Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, EPE foram 
selecionados de uma coorte armazenada no Biobanco-IMM (Centro Académico de 
Medicina de Lisboa). No Biobanco estavam armazenadas as cabeças femorais de 
doentes com AR submetidos próteses artroplastia total da anca (n=12) e ainda uma 
amostra de sangue. Como controlos, doentes com osteoartrose (OA) e osteoporose 
(OP) foram escolhidos da mesma coorte, com igual distribuição de sexo, idade e 
índice de massa corporal que os doentes com AR. De cada cabeça femoral foram 
recolhidos dois cilindros de diferente diâmetro, para testes mecânicos de compressão, 
colorações estruturais com hematoxilina e eosina, imunohistoquímica e ainda 
quantificação da expressão génica do osso trabecular. Realizámos ainda quantificação 
sérica de marcadores de remodelação óssea, P1NP marcador para a formação e 
CTX-I marcador para a reabsorção óssea.  
Como modelo animal foram utilizados ratos Wistar com artrite induzida por 
adjuvante. Os valores do índice inflamatório, o peso e o perímetro do tornozelo foram 
registados ao longo dos 22 dias pós indução da doença e os animais foram 
eutanaziados ao vigésimo segundo dia. Após a eutanásia foi recolhida uma amostra 
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de sangue por punção cardíaca e os ossos longos e as vertebras foram também 
armazenados. Os níveis séricos dos marcadores de remodelação óssea (CTX-I e 
P1NP) foram quantificados. As vértebras foram recolhidas para histomorfometria, os 
fémures para testes mecânicos e quantificação do conteúdo mineral (por 
espectroscopia de energia dispersada por raios-X) e as tíbias para quantificação da 
expressão génica. 
Ao comparar os doentes com AR e OA, não encontrámos quaisquer diferenças nos 
marcadores séricos CTX-I e P1NP, nos testes mecânicos de compressão nem ao nível 
da expressão génica do osso. Na comparação entre doentes com AR e OP, não 
encontrámos diferenças nos marcadores séricos de formação e reabsorção óssea, 
nem nos testes de compressão. No entanto, ao nível da expressão génica, os doentes 
com AR têm menor expressão de COL1A1 (gene que codifica o colagénio), RANKL 
(fator de diferenciação dos osteoclastos), WNT10B (proteína sinalizadora da via de 
sinalização Wnt), DKK1 e SFRP1 (inibidores da via de sinalização Wnt). 
No modelo animal, Observámos que o marcador de reabsorção óssea (CTX-I) 
estava diminuídos nos ratos artríticos quando comparados com os saudáveis. Mais 
ainda, a percentagem de volume ósseo (BV/TV) estava diminuída nos ratos com artrite 
e a separação média entre as trabéculas (Tb.Sp) era maior nos ratos doentes em 
comparação com os saudáveis. O conteúdo de cálcio e fósforo estavam também 
diminuídos nos ratos com artrite o que se traduziu em piores propriedades 
biomecânicas. No entanto, não encontrámos qualquer diferença na expressão génica. 
Os resultados obtidos com o estudo em amostras humanas não nos permite 
comprovar a hipótese postulada. Os resultados obtidos com o modelo animal sugerem 
que os ratos artríticos sofrem têm maior reabsorção óssea, o que se traduz em menor 
percentagem de volume ósseo, maior espaçamento médio entre as trabéculas e 
menor percentagem dos minerais constituintes da hidroxiapatite, cálcio e fósforo. 
Estas observações refletem-se em piores propriedades mecânicas no osso artrítico, 
sendo que este atinge o ponto em que perde a elasticidade e sofre a primeira fratura 
com uma menor força aplicada. Apesar de não conseguirmos confirmar ao nível da 
expressão génica que os inibidores da via Wnt estavam aumentados ao nível do osso 
em ratos com artrite, a expressão de genes ligados ao osteoblasto (como o RANKL e 
o LRP6) estava diminuída nos ratos com artrite. 
Sendo assim, em amostras com artrite observamos que existe reabsorção óssea 
aumentada, e que existe um comprometimento nos osteoblastos que não lhes permite 
formar osso e assim compensar a excessiva atividade dos osteoclastos. Isto leva à 
perda de massa óssea e à perda de massa óssea o que leva a uma maior 
suscetibilidade a fraturas de baixa intensidade características de doentes 
osteoporóticos. Infelizmente não conseguimos comprovar a nossa hipótese de que os 
doentes com artrite têm um comprometimento nos osteoblastos devido à expressão de 
inibidores da via Wnt no osso. 
No futuro, serão necessários mais estudos para tentar compreender que 
mecanismos levam ao comprometimento dos osteoblastos e a íntima relação entre o 
sistema imune e o tecido ósseo. 
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Abstract 
 
Rheumatoid Arthritis (RA) is a chronic inflammatory autoimmune disease that 
affects the peripheral joints. It is characterized by infiltration of the synovial membrane 
by immune cells and by bone erosions. These patients have increased bone resorption 
with low bone formation, leading to loss of bone mass. The low bone formation rate 
observed in arthritis is due to impairment of osteoblast activity, most likely to a 
deregulation of the canonical Wnt pathway. Osteoblast proliferation and activity is 
regulated by the Wnt signaling pathway which itself is controlled by several inhihbitors 
like Dickkopf proteins and sclerostin. Wnt inhibitors are highly expressed on the 
synovial membrane of RA patients. Our hypothesis is that the high expression of Wnt 
inhibitors at the bone level leads to osteoblast impairment in RA.  
To test our hypothesis we collected the femoral heads of 12 RA patients as well as 
serum samples. We used gender and age matched osteoarthritis (OA) and 
osteoporosis (OP) patients as controls. Quantification of serum bone turnover markers, 
mechanical compressive tests, and trabecular gene expression was performed. We 
have also used Wistar rats with adjuvant induced arthritis. Rats were euthanized at 22 
days post-disease induction. Blood samples and bones were collected, to measure of 
bone turnover markers, perform histomorphometry, three-point bending, energy-
dispersive X-ray spectroscopy and bone gene expression.  
No differences were found on the comparison of RA and OA patients. No 
differences were found between RA and OP patients, except that RA patients have 
decreased expression lower osteoblast gene expression. Arthritic rats have, higher 
CTX-I levels, lower BV/TV and Tb.Sp., lower Ca and P percentage, and worst 
mechanical properties than healthy controls. No differences were found on gene 
expression.  
Concluding, arthritis-affected bones have an impairment of osteoblasts and 
consequently worst bone quality, mechanical properties and less mineral content. 
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Introduction 
 
Rheumatoid Arthritis  
Rheumatoid arthritis (RA) is a chronic inflammatory disease, characterized by 
inflammation of the joint lining tissues (synovia)1. The prevalence of the disease on the 
world population is around 1% with a higher incidence on women, approximately twice 
than in men2. The symptoms of the disease include chronic inflammation of the 
synovial joints, progressive destruction of cartilage and bone, severe joint pain and life-
long disability3. In the synovial membrane a proliferation of cells and infiltration of 
inflammatory cells occurs into the joint space4 resulting in the formation of a tissue 
named “pannus” around the surfaces of the articular cartilage and bone1. During 
chronic inflammation, the balance between bone formation and resorption is skewed 
towards osteoclast (OC)-mediated bone resorption. Unlike other rheumatic diseases, in 
sites adjacent to inflamed areas, within the bone of these patients there is little 
evidence of new bone formation suggesting that the inflammation impairs osteoblast 
(OB) activity. In fact, fully differentiated osteoblasts are rarely seen in arthritic bone 
erosions indicating that there is no major bone formation taking place in these 
lesions5,4. Therefore, osteoblast activity does not compensate the excessive bone 
resorption4. This failure to compensate occurs not only near the joints but also at non-
inflamed skeletal sites thereby contributing to the development of secondary 
osteoporosis (OP)6 and a consequence decreased bone mineral density, systemic 
bone fragility and fractures7,8. 
 
RA and immune system 
Activation of immune cells is a requirement for defense of the host against 
pathogens, however an increased activation of immune cells can result in tissue 
damage9. In RA joints, the over-expression of Receptor activated of Nuclear Factor- κ 
B ligand (RANKL) due to T-cells and synovial fibroblasts activation in the joints, 
induces osteoclast differentiation leading to an increase of osteoclast activity and 
consequently to pathological bone destruction10,4. As demonstrated by Lubberts and 
colleagues, in collagen-induced arthritis (CIA) mice, the number of cells expressing 
ligands and receptors involved in osteoclast differentiation is increased11. For example, 
in the pannus tissue from active RA patients, RANK and RANKL, which are required for 
osteoclast differentiation, are both increased as arthritis progresses and, in areas of 
abundant RANK expressing cells, tartrate-resistant acid phosphatase (TRAP) positive 
multinucleated osteoclasts are also present11,12.  
 
Animal models for RA studies 
There are several animal models of arthritis and the most common ones are 
rodents, like rat and mouse. Animal models for arthritis can be divided in two major 
groups: the induced and the spontaneous, being the first one more advantageous 
because we know what is the triggering mechanism of arthritis which gives rise to an 
immune response13. Animal models allow us to assess the early phase of arthritis and 
understand how disease induction occurs. One of the aims of using animal models is to 
understand RA pathology by the study of the early phase of disease, or the induction 
phase, in which symptoms are still not present, which is very difficult in RA patients as 
they already present symptoms when are diagnosed13. Besides that, several animal 
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models are also used to test anti-arthritic drugs which are either under preclinical or 
clinical investigation or are currently used to treat this disease14,15.  
 
Adjuvant-induced-arthritis (AIA) Wistar model 
Wistar rats belong to the Rattus norvegicus species and were first rat developed to 
serve as a model organism. Another important point to consider is the sexual 
maturation of the animals, which is achieved at eight-nine weeks, corresponding to a 
weight of 200-250g.  
The adjuvant-induced arthritis model was originally used to study the eicosanoid 
pathway and test non-steiroidal anti-inflammatory drugs (NSAIDS). Actually is 
frequently associated with DMARDs research (Disease-modifying antirheumatic drugs), 
sintetic or natural16.  
The AIA model is an induction model of arthritis, consisting of inoculation of a 
pathogen by intradermal injection, at the base of the tail17. This is an acute model of the 
disease, and disease onset occurs 10 days after the induction17,16. The disease 
reaches a plateau of inflammation around the 19th day of disease. As the prevalence of 
RA is higher in females, the majority of arthritis studies use female rats for the AIA 
model. 
As any other model, AIA rat has similarities and differences comparing with human 
RA. The main similarities are the symmetrical joint involvement, peripheral joints 
affected, persistent joint inflammation, synovial hyperplasia, inflammatory cell 
infiltration and marginal erosions. The main differences are the rapid onset of highly 
erosive polyarthritis, involvement of axial skeleton, no rheumatoid factor, 
gastrointestinal, genitourinary and skin involvement, bony ankylosis and extra-articular 
manifestations not typical of RA17. However the major advantage of using this model is 
that AIA Wistar rats arthritis resembles human RA at the level of genetic linkage and 
the immune response cells hence this rat model is also usually used to test several 
drugs against RA13.  
 
Bone 
Bone is a dynamic tissue that undergoes constant adjustment to preserve and 
achieve the shape and structure of the skeleton, maintain structural integrity and 
regulate mineral homeostasis18,19. 
 
Bone Microstructure 
At the microscopic level, bone is composed of a cortical and a trabecular portion. 
Cortical bone represents 80% of skeletal bone and is dense and compact with a lower 
turnover ratio. This type of bone constitutes the outer part of all bones, providing 
mechanical strength and protection20. The trabecular bone only composes 20% of the 
whole skeleton, and is found inside the long bones surrounded by cortical bone21. This 
kind of bone has a very porous structure, is much more elastic, and has a higher 
turnover rate. It provides mechanical support to bones, such as the vertebrae and 
femurs, and has an important role on calcium homeostasis20,. Inside the bone we can 
find the bone marrow, between trabecular porous and surrounded by cortical bone22. 
Both trabecular and cortical bone are composed of osteons, but cortical osteons have 
concentric layers of bone, while trabecular bone has parallel fibbers of collagen and 
hydroxyapatite crystals20. 
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Bone molecular structure 
Bone is a heterogeneous composite material composed by an inorganic or mineral 
phase of hydroxyapatite (Ca10(PO4)6(OH)2) crystals, and an organic phase of collagen 
and noncollagenous proteins, lipids and water23. These components provide hardness 
and viscoelasticity to bone tissue24. 
 
Inorganic component 
Hydroxyapatite is the major component of the mineral phase of bone23. These 
crystals are formed by calcium and phosphorus present in the bloodstream and both 
minerals suffer several transformations until their incorporation into the hydroxyapatite 
crystals. Vitamin D plays an important role on the correct organization of crystals on 
bone due to its involvement in the decarboxylation of osteocalcin (OCN)25, a protein 
that is responsible for correct deposition of calcium molecules between the 
phosphorus26. The hydroxyapatite crystals are then aligned with the collagen proteins 
to form fibrils and fibers24. 
 
Organic component 
The organic component of bone is composed mostly by collagen type I (90%) and 
non-collagenous proteins21. Collagen type I is synthesized by osteoblasts and is 
deposited in parallel or concentric layers (lamellar bone)21. There are several non-
collagenous proteins on bone, although the most important ones are OCN and alkaline 
phosphatase (ALP). The first one is involved in calcium binding and hydroxyapatite 
stabilization, and the second one is an enzyme responsible for pyrophosphate (PPi) 
hydrolysis to generate inorganic phosphate (Pi) which is crucial for the formation of 
hydroxyapatite20,27.  
 
Bone cells structure 
When a damage or microfracture occurs in the bone, the responsible cells come into 
action and those are osteoblasts, osteoclasts and osteocytes28,29. These three types of 
cells form the basic multicellular unit (BMU). 
 
Osteoblasts (OB) and the Wnt pathway 
Osteoblasts have two important functions on bone: they are responsible for bone 
formation and they modulate osteoclast differentiation by producing RANKL1 and 
macrophage colony-stimulating factor (M-CSF) 30,31. Osteoblasts also secrete 
osteoprotegerin (OPG), a decoy of receptor for RANKL, which in turn inhibits osteoclast 
formation32,28,18. Osteoblasts are derived from mesenchymal stem cells, which can also 
give rise to chondrocytes or adipocytes, depending on growth factors, hormonal 
regulators and transcriptional factors involved6,33,28. In the case of osteoblasts, the 
major osteogenic factors are Runt-related transcription factor 2 (Runx2), osterix (Osx) 
and β-catenin (Fig.1) 34,31.  
Runx2 is expressed at early phases of osteoblastogenesis and is responsible for 
mesenchymal cell commitment. This transcription factor is responsible for the 
expression of Osx, OCN and type I collagen (Col1a1)31. Osx is expressed at the final 
steps of this process, having an important role in the segregation of osteoblasts from 
osteochondrogenitors and also inducing the expression of OCN and Col1a134,31.  
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When these cells achieve the mature state they also express ALP and OCN, both 
involved in matrix production28. OCN (after carboxylation) attracts calcium ions and 
incorporates them into hydroxyapatite crystals, consequently stopping bone 
formation35,36,37. When osteoblasts lose their synthesis capacity they either become 
lining cells, osteocytes or they die by apoptosis (Fig.1)4,33. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Osteoblast commitment and differentiation is strongly dependent on the Wnt/β-
catenin signaling (canonical Wnt pathway; Fig.2)28. Canonical Wnt pathway determines 
the fate of mesenchymal stem cells38.  
Briefly, in the absence of WNT proteins, GSK-3β phosphorilates β-catenin, which is 
degraded and the osteoblast signaling cascade is blocked, so the stem cells become 
chondrocytes or adipocytes30,38. When Wnt proteins are present, they bind to the 
frizzled receptor and a low-density lipoprotein receptor-related protein (LPR5/LRP6), 
activating the signaling cascade1. These receptors transduce a signal to a complex 
formed by dishevelled protein (Dsh), glycogen synthase kinase-3β (GSK-3β), axin and 
adenomatous poluplosis coli (APC), which promotes the phosphorilation and inhibition 
of GSK-3β39,40. As result, β-catenin can accumulate in the cytoplasm and translocate to 
the nucleus where the expression of the transcription factors T-cell factor/lymphoid 
enhancer factor (TCF/LEF) and consequently the expression of osteoblast related 
genes and OPG40. The activation of the Wnt signaling pathway promotes stem cell 
differentiation into ostoblasts. The increase of this signaling pathway also leads to 
inhibition of osteoclastogenesis by inducing the expression of OPG by osteoblasts39,30.  
When the Wnt pathway is activated, osteoblast differentiation occurs, but in the 
presence of antagonists like DKK1, secreted frizzled related proteins (sFRPs), SOST 
Figure 1 Pathways that are essentialfor osteoblast differentiation and activation. Mesenchymal stem cells 
are able to give rise to myoblasts, chondrocytes, or adipocytes when the Wnt pathway is not activated. On 
the contrary, when this pathway is active, osteoblast commitment and differentiation occurs. During 
osteoblastogenesis, Runx2 and Osx are also essential factors. At the end of osteoblasts life, they become 
osteocytes, lining cells or die. Adapted from 
4
. MyoD - myogenic differentiation; Sox9 - SRY (sex 
determining region Y)-box 9; PPARy - peroxisome proliferator-activated receptor y; Runx2 - runt-related 
transcription factor 2; Osx – osterix. 
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or Wnt inhinitory factor-I (Wif-I), the signaling is inhibited38,40. DKK and SOST are the 
most well studied endogenous Wnt inhibitors.  
 
 
Figure 2 Wnt pathway
41
. On the left, in the absence of Wnt proteins, GSK-3β phosphorylates β-catenin, so 
that it undergoes proteossomal degradation. On the right, Wnt proteins bind to the receptor LRP5/LRP6, 
inhibiting GSK-3β and allowing the accumulation of β-catenin which translocates to the nucleus and 
induces the expression of LEF/TCF.  LRP5 - low-density lipoprotein receptor-related protein 5; LRP6 - low-
density lipoprotein receptor-related protein 6; Dsh - dishevelled protein; APC - adenomatous poliposis coli,  
GSK-3β - glycogen synthase kinase-3β; TCF - T-cell factor; LEF - lymphoid enhancer factor. 
 
 
DKK1 is produced by osteocytes and osteoblasts and binds to LRP6 with high 
affinity, and to the Kremen28. Kremen2, DKK1 and LRP6 form a complex that promotes 
removal of the Wnt receptor from the plasma membrane by endocytosis40,42. DKK1 
expression is also induced by TNF9. DKK2 acts like an agonist or an antagonist of 
LRP6 depending of the presence of Kremen2. When Kremen2 is absent, the Wnt 
signaling pathway is activated, but in the presence of Kremen2 it is inhibited28. 
Sclerostin is the product of the SOST gene, which mainly expressed by 
osteocytes43. Moreover, this protein is secreted by osteocytes in response to a 
mechanical force, arresting bone formation44. Sclerostin binds to the LRP5/6 co-
receptor, so β-catenin is sequestered and degraded, therefore sclerostin acts as a Wnt 
inhibitor28.  
 
Osteocytes (OCY) 
Osteocytes are osteoblasts that become entrapped into the bone matrix. This is the 
most abundant cell type on bone and they are found in lacunae on the mineralized 
matrix19. They communicate with each other and with other cells such as osteoblasts 
and osteoclast progenitors through an extensive system of canaliculi33,45. Osteocytes 
are able to sense bone microfractures, thereby signalling the need for repair46. 
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Osteocytes can also control mineral homeostasis45. The death of osteocytes by 
apoptosis signals the presence of damage on its location and is considered the 
initiation of targeted remodeling28,19. In recent years the role of osteocytes has been 
appreciated in the control of bone mass through the discovery of SOST and DKK1, 
produced mainly by these cells. Both SOST and DKK1 play a critical role in the 
inhibition of bone formation by inhibiting with the Wnt pathway46.  
 
Osteoclasts (OC) 
Osteoclasts are multinucleated giant cells formed by the fusion of mononuclear 
progenitors from monocyte-macrophage lineage cells32,30. These cells are specialized 
in the removal of mineralized bone matrix30. Differentiation of osteoclasts occurs in 
response to M-CSF and RANKL produced mainly by osteoblasts but is blocked by 
OPG, also produced by osteoblasts18,30.  
 
Bone remodeling process 
The remodeling process occurs throughout life and has a pivotal role in the 
maintenance of the mechanical integrity of the skeleton, repair of fractures and mineral 
homeostasis47. The remodeling process consists of five phases: 
 
1. Activation 
The first phase involves the detection of a signal, such as structural damage, 
leading to recruitment and activation of osteoclasts precursors from the circulation18,21. 
 
2. Resorption 
Osteoblasts respond to signals generated by osteocytes and the expression of OPG 
is reduced with an increase of M-CSF and RANKL production to promote osteoclast 
formation and activation20. Osteoblasts also produce matrix metalloproteinases (MMPs) 
which degrade the unmineralized osteoid facilitating osteoclast attachment33. When 
they attach an isolated microenvironment known as the “sealing zone” is created. The 
osteoclast secretes hydrogen ions to the sealing zone creating an acidic environment 
allowing the dissolution of the mineralized matrix. Then, a set of collagenolytic 
enzymes, in particular cathepsin K, have the low pH necessary to degrade the organic 
bone matrix18,48. 
 
3. Reversal 
After resorption the Howship’s lacunae remains covered with undigested 
demineralized collagen matrix, and the cells responsible for the removal of matrix 
debris (osteomacs - bone macrophages) act during this phase18.  These cells may play 
a role on the receiving or producing signals that allow the transition from bone 
resorption to bone formation21. 
 
4. Formation 
Mechanical stimulation and parathyroid hormone (PTH) can lead to bone formation 
via osteocyte signals. Under resting conditions, osteocytes secrete sclerostin that binds 
to LRP5/6 and impairs Wnt signaling, an inducer of bone formation18. Mechanical strain 
and PTH inhibit osteocyte expression of sclerostin, removing the inhibition of Wnt 
signaling and allowing Wnt-directed bone formation, so osteoblast progenitors return to 
resorption lacunae, differentiate into osteoblasts and form bone. Collagen type I is the 
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primary organic component of bone, and non-collagenous proteins add the remaining 
organic material. Ultimately, hydroxyapatite is incorporated into this newly deposited 
osteon24. 
 
5. Termination 
The termination signals to cease the remodeling process are still unknown, although 
we believe that when osteoblasts become embedded in the mineralized matrix and 
differentiate into osteocytes, their sclerostin expression increases bringing the end of 
the remodeling cycle18. At the end of the remodeling process the quantity of resorbed 
bone should be equal to the total of formed bone21. 
 
Bone turnover markers 
Bone turnover markers are biochemical products usually measured in blood or urine 
that allow the quantification of the bone’s metabolic activity49,50. These molecules are 
thought to have no function in controlling skeletal metabolism and they are classified as 
bone formation or bone resorption markers50. Total OCN, ALP bone isoenzyme and the 
C and N-propeptide of type I collagen (P1NP) are examples of the most used bone 
formation markers, while type I collagen cross-links (pyridinoline-PYD and 
deoxypyridinoline-DPD), N-terminal cross link telopeptide of type I collagen (NTX) and 
C-terminal cross-link telopeptide of type I collagen (CTX-I) are the most common 
markers of bone resorption51. P1NP released to circulation is a product of enzyme 
cleavage of procollagen type I during bone matrix formation, while CTX-I is released 
during cathepsin K activity during bone resorption50. 
 
 
 
Objective 
In RA, a trigger leads to immune system hyper-activation. As the immune system 
and bone are connected, this triggers leads to an excess of bone resorption by 
osteoclasts, which in normal conditions is compensated by the formation of new bone 
carried out by osteoblasts. However, pro-inflammatory cytokines disrupt not only the 
OC-OB communication but also the Wnt signalling pathway. The upregulation of Wnt 
antagonists like DKK1 has been implicated in the suppression of osteoblast activity 
during inflammation-induced bone loss5,42. Reduced Wnt activation and an increase in 
osteoclast activity leads to an increase in osteoclast-mediated bone resorption in RA52.  
Therefore, our hypothesis is that Wnt inhibitors are upregulated on bone leading to 
osteoblast loss of function. Our goal is to study bone at several levels, beginning on the 
gene expression of osteoblast markers and Wnt related genes and also access the 
bone turnover ratio and determine the bone quality and microstructure. 
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Material and Methods 
 
Patients 
This was a nested case study from a cohort of 1035 consecutive patients 
undergoing total hip replacement surgery at Lisbon Academic Medical Centre, with 
bone samples stored in a biobank (Biobanco-IMM) in Lisbon. Patients who were 
diagnosed with RA according to the 2010 ACR/EULAR revised classification53 and 
submitted to total hip replacement surgery between 2007 and 2014 were selected from 
the biobank collection and included in this study. Patients were excluded if other 
causes of secondary OP were present, such as malignancies, untreated thyroid 
disease, terminal renal disease or hypogonadism and if they were under anti-
osteoporotic treatments.  
Two other groups undergoing hip arthroplasty due to hip fragility fracture or 
Osteoarthritis (OA), matched to gender, age and body mass index (BMI), and without 
any secondary causes for Osteoporosis (OP), were selected from the biobank to be 
used as control groups.  
All patients were asked to complete a clinical questionnaire at the time of surgery in 
order to assess clinical risk factors associated with OP, such as age, gender, BMI, prior 
fragility fracture, family history of hip fracture, long-term use of oral corticosteroids 
(≥3months), current smoking and alcohol intake (>3 units/day) and past and current 
medication. Four days after the surgery, Bone Mineral Density (BMD) of the 
contralateral hip was measured by dual X-absorptiometry (DXA) scan using a Lunar 
Prodigy densitometer (Lunar Prodigy, GE Healthcare at the Rheumatology and Bone 
Metabolic Diseases Department of Hospital de Santa Maria. For RA patients, disease 
duration, age at disease onset, rheumatoid factor, C-reactive protein (CRP), disease 
activity score (DAS28 ESR3V), presence of erosions, and RA therapy were also 
assessed.  
Serum samples were collected from patients at the time of surgery for biomarkers 
measurement. The femoral heads removed from the patients were collected and 
processed. From the femoral epiphysis two cylinders were drilled, one used for 
mechanical tests (15 mm diameter), while the other (18 mm diameter) was cut and 
used for immunohistochemistry. Small pieces of trabecular bone were collected and 
frozen for gene expression study. 
Written informed consent was obtained from all patients. This study was conducted 
in accordance with the regulations governing clinical trials such as the Declaration of 
Hensinki, as amended in Fortaleza (2013), and was approved by the Hospital de Santa 
Maria Ethics Committee. 
 
Rat model 
Wistar AIA rats (N = 21) were purchased from Charles River Laboratories 
International. Eight-week-old females weighing 200–230 g were maintained under 
speciﬁc pathogen free (SPF) conditions and all experiments were approved by the 
Animal User and Ethical Committees at Instituto de Medicina Molecular, according to 
the Portuguese law and the European recommendations.  
At Charles River, nine animals were inoculated under isoflurane anesthesia by 
subcutaneous injection of complete Freund’s adjuvant (CFA) containing 
Mycobacterium butyricum in the right paw, which causes a profound systemic 
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inflammatory reaction resulting in severe joint swelling and destruction54,17. As controls, 
12 healthy Wistar rats were used.  
The inﬂammatory score, ankle perimeter and body weight were measured during the 
study period every other day. Inflammatory signs were evaluated by scoring each joint 
in a scale of 0-3 (0 - absence of any sign, 1 - erythema, 2 - erythema and swelling, 3 - 
deformity and functional impairment). The total score of each animal was defined as 
the sum of the partial scores of each affected joint. Rats were sacrificed after 22 days 
of disease evolution when they were 3 months of age.  
At the time of sacrifice vertebrae and long bones, such as femur and tibia, were 
collected for histological evaluation, RNA extraction and three point bending test. Blood 
samples were collected by cardiac puncture for bone turnover markers assessment.  
 
 
Bone turnover markers measurements 
Carboxy-terminal cross-linked telopeptides of type I collagen (CTX-I) and amino-
terminal propeptides of type I procollagen (P1NP) were measured by enzyme linked 
immunosorbent assay (ELISA) in human and rat serum. Human CTX-I and human 
P1NP ELISA kits (SunRed Biological Technology) and rat (Immunodiagnostic Systems 
Ltd) were used according to the manufacturer’s instructions and read in a Tecan Infinite 
200 PRO (Tecan Group). 
 
Histological techniques 
Sample processing 
Trabecular bone from femoral epiphysis was fixed in formaldehyde 10% (VWR) for 7 
days, decalcified in Ethylenediaminetetraacetic acid(EDTA, Promega) 10% for 14 days, 
dehydrated in increased alcohol concentrations (70%, 96%,100%, 24 hours each) and 
embedded in paraffin. Five sections with 5µm thickness were cut in a microtome (Leica 
RM2145, Leica). Before hematoxylin and eosin staining or immunohistochemistry the 
samples deparaffinized with xylene and hydrated with decreasing alcohol solutions 
(100%, 96%, 70%), ten minutes each.  
 
Hematoxilyn and eosin staining 
Hematoxylin and eosin staining (H&E) is one of the principal stains in histology. It is 
the most widely used stain in medical diagnosis, allowing the differentiation between 
cytoplasm (pink) and nucleus (blue) providing a good staining for standard analysis55. 
Hematoxilyn has a basic pH with affinity to acid structures, while eosin has an acid pH 
with affinity to basic structures.  
The staining was performed with hematoxilyn (Bio-Optica) for five minutes, and five 
minutes of warm running water for hematoxilyn oxidation. The samples were then 
immersed in alcohol 70% before the counterstaining in alcoholic eosin (Thermo 
Scientific). Slides were dehydrated with increasing alcohol solutions (70%, 96%, 100%) 
for thirty seconds each, and after fifteen minutes in Xylene were mounted with Quick-D 
mounting medium (Klinipath). 
 
Immunohistochemistry of femoral epiphysis 
Immunohistochemistry is a technique based in the principle of antigen-antibody binding 
that allows the identification of proteins of interest in the tissue samples56.  
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As our samples were embedded with paraffin, the antigen sites were cover so we 
performed antigen retrieval to uncover the epitopes and restore the immunoreactivity. 
Antigenic retrieval was performed with Proteinase K (Sigma-Aldrich), incubating for 
twenty minutes at 37ºC and then 10 minutes at room temperature. Endogenous 
peroxidase was blocked with a solution of 1.5 % hydrogen peroxide in methanol (VWR) 
for 15 minutes at room temperature. Total proteins were blocked with PBS/BSA 1% 
(Fluka) for twenty minutes. Samples were incubated with primary antibody for one hour 
at room temperature. An envision polymer with horseradish peroxidise ((1µg/mL, HRP, 
Dako) was used as a secondary antibody. All washes were performed with PBS/Triton 
(Sigma-Aldrich) or distilled water.  At the end, 3, 3'-diaminobenzidine (DAB, Dako) was 
used as development solution. Slides were counterstained with Harris hematoxylin 
(Bio-Optica,), dehydrated with increasing alcohol solutions (70%, 96%, 100%) for thirty 
seconds each, fifteen minutes in Xylene and mounted Quick-D mounting medium. 
Negative control follows the same protocol except the primary antibody staining.  
The antibodies used were anti-DKK1 (ab109416, 1:500), anti-osteocalcin (ab13420, 
10µg/ml) and anti-SOST (ab63097, 1:50), all from AbCam.  
Slides were observed at a brightfield microscope (Leica DM2500, Leica) and 
photographed with camera CCD (Leica). DKK1 samples were scored with 1 (0-25% 
staining osteocytes), 2 (26-50% staining osteocytes), 3 (51-75% staining osteocytes) or 
4 (76-100% staining osteocytes). Slides stained with osteocalcin were scored with 1 
(sample without osteoblasts), 2 (sample with less of 50% of labelled osteoblasts) and 3 
(sample with more than 50% of labelled osteoblasts). SOST was scored with 1 (0-25% 
staining osteocytes), 2 (26-75% staining osteocytes) and 3 (76-100% staining 
osteocytes).  
 
Histomorphometry of rat vertebrae 
Histomorphometry is a technique used for the quantitative study of the microscopic 
organization and structure of a tissue, such as bone, in 2D allowing the extrapolation 
for 3D results. Microarchitecture can be assessed by static parameters, such as 
trabecular thickness (Tb. Th) and trabecular separation (Tb.Sp). These architectural 
parameters are related to the bone volume fraction (BV/TV) value. BV/TV value is the 
percentage of area occupied by calcified bone in relation to the total sample area. 
Tb.Th is the medium distance across individual trabeculae and Tb.Sp is the medium 
distance between trabeculae of our region of interest57. 
We used the L4 vertebrae to study bone fragility by histomorhometry. The samples 
went through five phases: fixation with ethanol 70% for 7 days, dehydration with 
increasing ethanol concentration from 96% to 100% during two days each, clearing 
with xylene for 4 hours, impregnation with methyl methacrylate (Sigma-Aldrich) for a 
minimum of 72 hours, and embedded in a solution of dimethylaniline 2% (Merck) in 
methyl methacrylate (Sigma-Aldrich). Dimethylaniline was used as catalyst to promote 
the polymerization. During these five steps the samples were maintained at 4ºC.  
After the polymerization, the samples were cut in a microtome (Leica) with a 
tungsten blade (Leica), enabling the cut of calcified bone samples. We cut three 
sections with 5µm of thickness. Slides coated with gelatine chrome alum (Panreac) 
together with polyethylene film were used to keep the sample attached. Samples were 
then stained with aniline blue (VWR). Briefly, the slides were immersed in ponceau 
fuchsin (Sigma-Aldrich) for two minutes, washed with acetic water 1% (Sigma-Aldrich) 
and distilled water. Thereafter slides were incubated with aniline blue 0.2% (Sigma-
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Aldrich) for fifteen minutes. Lastly slides were washed with distilled water and then 
dehydrated with increasing ethanol solutions (70%, 96%, and 100%), immersed in 
xylene and mounted with Quick-D mounting medium. The entire preparations were 
observed with Leica DM2500, objective 1.25x and photographed with camera CCD 
(Leica). Samples were than analysed using Bone J plugin58 (England) of Image J 
software59,60 (NIH). For each sample the following structural parameters were 
evaluated: Bone volume (%) (BV/TV), Trabecular thickness (Tb.Th) (µm) and 
Trabecular separation (Tb.Sp.) (µm). 
 
Energy-dispersive X-ray spectroscopy 
EDX consists in the emission of a solid sample with an electron beam in order to 
obtain a localized chemical analysis. This method is based on the difference of energy 
caused by the excitation of an electron that causes its injection to the next orbital of the 
atom and an electron of an outer orbital of higher-energy then fills the hole. The 
difference in energy between the higher-energy orbital and the lower energy orbital is 
released in the form of an X-ray. This technique was used in order to quantify the 
calcium and phosphorus concentration in the rat bone samples. 
After rat femurs collection, samples were dried for 46 hours, with a multipurpose ice 
condenser (ModulyoD-230, Thermo Savant) operated at a nominal temperature of -50 
˚C, in order to remove excess of water. The femurs were pulverized using a mortar and 
pestle, without liquid nitrogen. The measurements of bone powder were performed with 
a 4 kW commercial wavelength dispersive X-ray fluorescence spectrometer (Bruker S4 
Pioneer), using a Rh X-ray tube with a 75 mm Be end window and a 34 mm diameter 
collimator mask. Measurements were performed in helium mode and using high-
density polyethylene X-ray fluorescence sample cups with 35.8 mm diameter 
assembled with a 4 mm prolene film to support the bone sample. The polyethylene cup 
was placed in steel sample cup holders with an opening diameter of 34 mm. The 
percentage of calcium and phosphorus was measured in the analysed samples. 
 
Mechanical Tests 
Mechanical tests allow us to determine the behaviour of bone under a load. Briefly, 
the Young’s modulus is a measure the stiffness of a material, the strength or yield 
strength is defined as the stress at which a material begins to deform plastically, and 
the toughness is the ability of a material to absorb energy and plastically deform 
without fracturing61 (Fig.1).  
 
Compression tests of human bone 
The 15 mm cylinders of human bone were defatted for 3 hours using a chloroform 
and methanol (1:1) solution and were hydrated overnight in PBS 1x prior to testing. The 
tops of the cylinder were cut and polished, so that the samples are composed only by 
trabecular bone. Compression tests were performed in a universal testing machine 
(Instron 5566™, Instron Corporation) with a 10-kN load cell and a cross-head rate of 
0.1 mm/s. Stress–strain curves were obtained for each sample using the Bluehill 2 
software (Instron Corporation). This software has the ability to build stress–strain 
representations from load displacement points, normalized for the dimensions of the 
specimen. The respective curves were analysed in order to obtain the mechanical bone 
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parameters: stiffness (Young’s modulus), strength (yield stress), and toughness 
(energy absorbed until fracture)62 - see Fig.3. 
 
 
 
 
 
Three-point bending of rat femur 
For the three-point bending test the femur was placed on two supporting pins a set 
5mm apart and a third loading pin is lowered from above at a constant rate until sample 
failure. The bending load was applied to the femoral midshaft perpendicularly to the 
long axis of the bone until failure of the specimen63. Tests were performed using the 
same equipment and analysis software as in the mechanical compression tests, under 
the same conditions. The respective curves were analysed in order to obtain the 
mechanical bone parameters: yield stress and ultimate stress (Fig. 4). In figure 2, yield 
point corresponds to yield stress and ultimate point corresponds to ultimate stress. 
Figure 3 Graphical representation of the parameters evaluated from bone mechanical 
compression test. The yield point is the point where a material loses its elastic behaviour and 
occurs the first microfractures; Young’s modulus or Stiffness is a measure of bone resistance 
to deformation; Toughness or energy until failure is the energy required to induce failure of 
the structure which corresponds to the Fracture of bone structure
62
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Figure 4 Graphical representation of the parameters evaluated by three point bending of femurs
63
 . Yield 
point: the point where the bone tissue ceases to behave elastically; Ultimate point: is the maximum 
load that bone tissue can support while being stretched or pulled before failing or breaking (slope of the 
curve between the origin and the first yield point): is a measure of the stiffness of an elastic material like 
bone tissue; The trace line correspond to arthritic rats and the full line to healthy rats; Yield point 
corresponds to yield stress and ultimate point corresponds to ultimate stress 
 
 Gene expression studies 
Gene expression allows us to understand the effect of inflammation in bone at the 
molecular level. In this study we performed quantitative real-time-polymerase chain 
reaction (qRT-PCR) in order to evaluate if selected genes are being more or less 
expressed when patients have RA or rats have arthritis.  
 
RNA extraction 
Without defrosting the sample, small trabecular pieces were pulverized using a 
mortar and pestle. Bone powder was placed in TRIzol reagent and homogenized. Lipid 
solubilisation was performed with chloroform and the supernatant containing the RNA 
was preserved. Proteinase K digestion was performed at 55ºC. For the precipitation of 
RNA we used ice-cold isopropyl alcohol and the pellet containing the RNA was 
preserved and washed with ethanol 75%. The remaining RNA pellet was dissolved in 
RNase/DNase-free water. RNA was cleaned using a commercial kit (RNeasy mini kit, 
Qiagen) according to the manufacturer instructions. Genomic DNA contaminants were 
removed with DNaseI treatment (Qiagen). For rat samples the RNA extraction was 
performed using the same protocol, but instead of bone pieces we used the left tibia. 
RNA concentration was determined spectrophotometrically (Nanodrop ND-1000 
Spectrophotometer, Thermo Fisher Scientific). RNA was stored at –80ºC and later 
used for complementary (c)DNA synthesis. 
 
cDNA synthesis 
cDNA synthesis was performed on 3ng of RNA from each sample using the 
DyNAmo cDNA synthesis kit (Thermo Fisher Scientific) and 300 ng of random 
hexamers according to the manufacterer’s instructions. The reverse transcription 
reaction was performed on a thermocycler at 37ºC for 30 minutes for cDNA synthesis 
followed by a 85ºC for 5 minutes incubation to stop the enzyme activity. The cDNA 
template were stored at -20ºC for qRT-PCR. 
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Quantitative real time-polymerase chain reaction (qRT-PCR) 
Each cDNA sample with a concentration of 3ng/µL was amplified in duplicate with 
DyNAmo Flash SYBR green qPCR kit (Thermo Fisher Scientific) in the RotorGene 
6000 thermocyler (Qiagen) according to the manufacturer‘s instructions. The reaction 
starts at 50ºC for 2 minutes and then 95ºC for 7 minutes, followed by denaturation at 
95ºC for 10 seconds and annealing at 60ºC for 10 seconds for 50 cycles. The reactions 
were validated by the presence of a single peak in the melt curve analysis.  
The results were analysed by the standard curve method. The standard curves were 
made using cDNA templates with known RNA concentration from individuals with 
normal BMD and without clinical risk factors for osteoporosis. The cycle threshold (CT) 
is defined as the number of cycles required for the fluorescent signal to cross the 
threshold and exceed the background level. The efficiency of the PCR should be 
between 90-100%, which means that for each cycle the amount of product doubles. 
The conversion of the CT value in relative expression levels was performed applying 
the equation 10(CT – Y intersect /slope) in which slope and Y intersect were extracted from 
standard curve64,65. Primers for the housekeeping and target genes were designed 
using the software Probefinder66 in order to anneal in separate exons preventing 
amplification of contaminating DNA. The values obtained with qRT-PCR were 
normalized with the housekeeping gene phosphomannomutase 1 (PMM1) for human 
samples and Ribossomal protein 29 (RSP29) for rat samples. Primers sequence and 
details can be found in Annex 1. 
 
Statistical analysis 
Results are presented as mean and standard deviation for continuous variables and 
categorical variables are presented as relative frequencies.  
In humans, the RA patient group of interest was compared with the primary OP 
control group and OA control group. OP control group allow us to compare the 
inflammatory interaction of disease and the OA control group, the loss of bone mineral 
density. The normality of continuous variables was tested with Shaphiro-Wilk test, and 
either Student’s t test or the non-parametric Mann-Whitney test was used to compare 
RA with OP and RA with OA. In rats we used the same approach to compare the 
healthy with the arthritic group.  
For categorical variables, chi-squared test was used. Significance level was set as 
0.05. Statistical analysis was performed using the Statistical Package for Social 
Sciences manager software, version 17.0 (SPSS, Inc). All graphics were created using 
GraphPrad Prism sofware, version 5 (GraphPad Software, Inc). 
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Results 
 
Human samples – RA vs OA 
 
Patient characteristics 
For this study 12 patients with RA were recruited. As controls age and sex matched 
14 patients with OP, and 14 with OA were also recruited (Tables 1 and 4). RA patients 
have a mean age of 65±15 years, and this population was composed by 83% of 
women with disease duration of 4.74±3.29 years. The mean t-score for these patients 
was -2.72±0.78 and they had a mean BMD of 0.68±0.06 g/cm2. These patients have a 
mean DAS28 3V of 4.19±2.13. All RA patients were under corticosteroid therapy, but 
only 72.7% of them were under methrotrexate, and only one was under biological 
therapy (Etanercept). Sixty percent of RA patients were positive to anti-cyclic 
Citrullinated Peptide (anti-CCP) and 56% were positive to rheumatoid factor (Table 1). 
 
 
Table 1 Clinical and biochemical characteristics of RA and OA patients 
 
RA (n=12) OA (n=14) p value 
Age (years) 65±15 68±6 0.938 
Women (%) 83 71 0.468 
BMI (Kg/m2) 25.99±4.73 28.33±4.56 0.226 
T-score -2.72±0.78 - - 
BMD (g/cm2) 0.68±0.06 - - 
DAS28 3V 4.19±2.13 - - 
Methotrexate (%) 72.7 - - 
Corticosteroids (%) 100 - - 
Anti-CCP + (%) 60 - - 
RF + (%) 55.6 - - 
Disease duration (years) 4.74±3.29 - - 
Values represent mean±standard deviation; RA - Rheumatoid arthritis; OA - 
Osteoarthritis: BMI - Body mass index; BMD – Bone mineral density; Anti-CCP - 
Anti-cyclic citrullinated Peptide; RF – Rheumatoid factor 
 
 
The OA population has a mean age of 68±6 years, and is composed by 71% of 
women. None of OA patients were under corticosteroids therapy (Table 1).  
 
 
 
Bone turnover markers 
When comparing serum bone turnover markers between RA and OA patients, no 
statistically significant differences were found. The CTX-I/P1NP ratio which reflects the 
balance between bone resorption and bone formation, no differences were found 
(Fig.5). 
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Figure 5 Levels of CTX-I, a marker of bone resorption, and P1NP, a marker of bone formation, and the 
calculated ratio of CTX-I/P1NP in RA and OA groups. Lines represent the median and interquartile range 
(10-90); RA - Rheumatoid arthritis; OA – Osteoarthritis; CTX-I - C-terminal cross-link telopeptide of type I 
collagen; P1NP - N-propeptide of type I collagen 
  
 
Mechanical Compression Tests 
To access bone mechanical characteristics, we performed compression tests and 
compared three parameters between RA and control groups: yield stress, Young’s 
modulus and energy until failure.  
No differences were found in any of these parameters when RA patients were 
compared with the OA patients (Table 2) but the young’s modulus was slightly 
decreased in RA patients. 
 
 
Table 2 Bone mechanical characteristics in RA and OA patients  
 
RA (n=12) OA (n=14) p value 
Yield stress (MPa) 5.20 [2.21-9.02] 4.41 [2.48-10.70] 0.447 
Young's modulus (MPa) 267.5 [88.33-544.0] 425.1 [224.90-690.0] 0.141 
Energy until failure (MJ/m
3
) 0.05 [0.02-0.12] 0.02 [0.01-0.19] 0.885 
Values represent median [interquartile range 25-75]; RA - Rheumatoid arthritis; OA - Osteoarthritis: 
MPa - Mega Pascal; MJ - Mega Joule 
 
 
 
Gene expression 
In order to determine the effect of RA at the gene level, we performed gene 
expression of trabecular bone. None of the studied genes shows statistically significant 
differences, although we can see a tendency for most of osteoblasts markers 
(COL1A1, OPG, RANKL, OSX and LRP6) to be increased in RA patients when 
compared to OA patients. WNT10B, a protein of the Wnt family and is receptor SOST 
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have a higher expression in OA group than RA, however with no statistically significant 
difference (Table 3). 
 
 
Table 3 Gene expression from trabecular bone of RA and OA patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Human samples – RA vs OP 
 
Osteoporosis population 
The RA population is already described above. The OP patients have a mean age of 
73±6 years, with 86% of women. These patients have a mean T-score of -2.67±0.60 
and mean BMD of 0.67±0.09 g/cm2.  Both RA and OP patients have similar BMD and 
T-score (Table 4). 
 
 
 
 
 
 
 
 
RA (n=12) OA (n=14) p value 
COL1A1 0.13 [0.04-0.24] 0.03 [0.01-0.09] 0.054 
RUNX2 0.16 [0.01-0.23] 0.11 [0.05-0.17] 0.580 
OSX 0.15 [0.002-0.29] 0.05 [0.02-0.36] 0.794 
OPG 0.24 [0.02-0.73] 0.08 [0.01-0.16] 0.123 
RANKL 0.53 [0.02-2.14] 0.08 [0.02-0.16] 0.158 
RANKL/OPG 2.23 [0.28-5.72] 1.01 [0.32-4.32] 0.762 
ALP 0.07 [0.01-0.34] 0.03 [0.02-0.05] 0.235 
OCN 0.02 [0.004-0.32] 0.03 [0.007-0.09] 0.821 
SEMA 3A 0.36 [0.16-1.79] 0.25 [0.06-0.29] 0.159 
WNT10B 1.70 [0.17-2.07] 10.42 [0.03-40.91] 0.342 
LRP5 0.08 [0.02-0.13] 0.07 [0.03-0.14] 0.944 
LRP6 0.16 [0.01-0.31] 0.04 [0.03-0.09] 0.973 
SFRP1 0.03 [0.003-0.14] 0.04 [0.01-0.19] 0.434 
DKK1 0.01 [0.04-0.24] 0.01 [0.004-0.04] 0.762 
DKK2 0.07 [0.01-0.17] 0.02 [0.01-0.07] 0.214 
WIF1 2.29 [0.45-16.05] 2.42 [0.93-6.57] 0.768 
SOST 0.03 [0.01-0.28] 0.20 [0.05-0.80] 0.157 
Values represent median [interquartile range 25-75]; Gene expression is normalized to 
the housekeeping gene PMM1 (phosphommanomutase-1); RA - Rheumatoid arthritis; 
OA - Osteoarthritis: COL1A1 - Collagen, type I alpha 1; RUNX2 - Runt-related 
transcription factor 2; OPG – Osteoprotegerin; RANKL -  receptor activator of nuclear 
factor kappa B ligand; OSX – Osterix ; ALP – Alkaline phosphatase; OCN – 
Osteocalcin; SOST – slcerostin; WNT10B - Wingless-type MMTV integration site family, 
member 10B; LRP - Low-density lipoprotein receptor-related protein; SFRP1 - Secreted 
frizzled-related protein 1; DKK - Dickkopf-related protein; WIF1 - Wnt inhibitory factor 1; 
SEMA 3A - Semaphorin-3A 
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Table 4 Clinical and biochemical characteristics of RA and OP patients 
 
RA (n=12) OP (n=14) p value 
Age (years) 65±15 73±6 0.163 
Women (%) 83 86 0.867 
BMI (Kg/m2) 25.99±4.73 23.73±2.82 0.182 
T-score -2.72±0.78 -2.67±0.60 0.926 
BMD (g/cm2) 0.68±0.06 0.67±0.09 0.757 
DAS28 3V 4.19±2.13 - - 
Methotrexate (%) 72.7 - - 
Corticosteroids (%) 100 0 - 
Anti-CCP + (%) 60 - - 
RF + (%) 55.6 - - 
Disease duration (years) 4.74±3.29 - - 
Values represent mean±standard deviation; RA - Rheumatoid arthritis; OA - 
Osteoarthritis; BMI - Body mass index; BMD – Bone mineral density; Anti-CCP - Anti-
cyclic citrullinated Peptide; RA factor – Rheumatoid factor 
 
 
Bone turnover markers 
On the comparison of RA with OP patients we found a decrease in P1NP level in RA 
patients, although without reaching statistical significance. No differences were found 
on bone turnover ratio CTX-I/P1NP (Fig.6). 
 
Figure 6 Comparison between RA group and OP group of the serum bone markers quantification and 
bone turnover ratio; Lines represent the median and interquartile range (10-90); RA - Rheumatoid arthritis; 
OA – Osteoarthritis; CTX-I - C-terminal cross-link telopeptide of type I collagen; P1NP - N-propeptide of 
type I collagen 
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Mechanical Compression Tests 
When we compare the yield stress, Young’s modulus and energy until failure of RA 
and OP patients, no significant differences were found when comparing bone 
mechanical properties (Table 5). 
 
Table 5 Bone mechanical characteristics in RA and OP patients 
 
RA (n=12) OP (n=14) p value 
Yield stress (MPa) 5.20 [2.21-9.02] 3.61 [2.08-8.59] 0.598 
Young's modulus (MPa) 267.5 [88.33-544.0] 221.8 [140.20-329.4] 0.374 
Energy until failure (MJ/m
3
) 0.05 [0.02-0.12] 0.07 [0.03-0.16] 0.440 
Values represent median [interquartile range 25-75]; RA - Rheumatoid arthritis; OA - Osteoarthritis: 
MPa - Mega Pascal; MJ - Mega Joule 
 
Gene expression 
Gene expression of trabecular bone of OP patients was also performed and 
compared with the RA patients.   
We found that both COL1A1 (p=0.009) and RANKL (p=0.007) were significantly 
decreased in RA patients when compared with the OP group (Table 6 and Figure 7). 
Moreover we also found that, WNT10B (p=0.004), SFRP1 (p=0.016) and DKK1 
(p=0.005) are decreased in RA when compared to OP patients. No other significant 
differences were found, however there is a tendency for RA osteoblast gene 
expression to be decreased when compared to OP patients (Table 6).  
 
Table 6 Gene expression from trabecular bone of RA and OP patients 
 
RA (n=12) OP (n=14) p value 
COL1A1 0.13 [0.04-0.24] 0.91[0.02-2.39] 0.009 ** 
RUNX2 0.16 [0.01-0.23] 0.21[0.13-0.40] 0.136 
OSX 0.15 [0.002-0.29] 0.16 [0.07-52.31] 0.140 
OPG 0.24 [0.02-0.73] 0.55 [0.19-2.23] 0.176 
RANKL 0.53 [0.02-2.14] 5.25 [0.62-35.20] 0.007 ** 
RANKL/OPG 2.23 [0.28-5.72] 3.87 [3.01-6.46] 0.121 
ALP 0.07 [0.01-0.34] 0.21 [0.08-0.73] 0.100 
OCN 0.02 [0.004-0.32] 0.01 [0.003-0.02] 0.160 
SEMA 3A 0.36 [0.16-1.79] 0.57 [0.40-1.75] 0.439 
WNT10B 1.70 [0.17-2.07] 9.27 [2.75-11.29] 0.004 ** 
LRP5 0.08 [0.02-0.13] 0.51 [0.04-1.52] 0.132 
LRP6 0.16 [0.01-0.31] 0.80 [0.06-1.51] 0.140 
SFRP1 0.03 [0.003-0.14] 10.46 [0.05-22.91] 0.016 * 
DKK1 0.01 [0.04-0.24] 3.06 [1.41-31.13] 0.005 ** 
DKK2 0.07 [0.01-0.17] 0.30 [0.06-16.46] 0.110 
WIF1 2.29 [0.45-16.05] 5.44 [1.99-8.51] 0.695 
SOST 0.03 [0.01-0.28] 0.22 [0.06-145.80] 0.087 
Values represent median [interquartile range 25-75]; Gene expression is normalized to the 
housekeeping gene PMM1 (phosphommanomutase-1); **p<0.01; RA - Rheumatoid arthritis; OP - 
Osteoporosis; COL1A1 - Collagen, type I alpha 1; RUNX2 - Runt-related transcription factor 2; OPG - 
Osteoprotegerin; RANKL - receptor activator of nuclear factor kappa B ligand; OSX - Osterix ; ALP - 
Alkaline phosphatase; OCN - Osteocalcin; SOST - Slcerostin; WNT10B - Wingless-type MMTV 
integration site family, member 10B; LRP - Low-density lipoprotein receptor-related protein; SFRP1 - 
Secreted frizzled-related protein 1; DKK - Dickkopf-related protein; WIF1 - Wnt inhibitory factor 1; 
SEMA 3A - Semaphorin-3A 
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Figure 7 Osteoblast markers and Wnt-related genes with statistical difference between RA e OP patients. 
Bars represent median [interquartile range 25-75]; Gene expression was normalized to the housekeeping 
gene PMM1 (phosphommanomutase-1); *p<0.05, **p<0.01; RA - Rheumatoid arthritis; OA – 
Osteoarthritis; OP - Osteoporosis; COL1A1 - Collagen, type I alpha 1; RANKL -  receptor activator of 
nuclear factor kappa B ligand; WNT10B - Wingless-type MMTV integration site family, member 10B;  DKK 
- Dickkopf-related protein; SFRP1 - Secreted frizzled-related protein 1  
 
 
 
 
 
As mentioned by Caetano-Lopes and co-workers67, gene expression in bone 
fluctuates during fracture healing. For this reason we divided the fragility fracture 
patients (OP group) in three sub groups depending on the days between fracture and 
surgery: the first, until 3 days post-fracture, the second, between 4 and 7 days post-
fracture and the third with 8 or more days post-fracture. We found no significant 
differences throughout time in any of the analyzed genes (Fig.8). 
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Figure 8 Relative gene expression of osteoblast markers according to the time between fracture and 
surgery; Dots represent median values; gene expression was normalized to PMM1. COL1A1 - Collagen, 
typ e I, alpha 1; Runx2 - Runt-related transcription factor 2; OPG – Osteoprotegerin; RANKL -  receptor 
activator of nuclear factor kappa B ligand; OSX – Osterix ; ALP – Alkaline phosphatase; OCN – 
Osteocalcin; PMM1 - phosphomannomutase 1 
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Immunohistochemistry of femoral epiphysis 
Immunohistochemistry analysis could not be performed due to technical reasons. 
Femoral epiphyses were stored at -80ºC before sample processing. Due to this low 
temperature, most of the epitopes were destroyed. For this reason we could not 
confirm our gene expression results. In Fig.9 representative images of 
immuhistochemistry in selected samples of RA without epitope destruction are shown.  
 
 
 
 
Figure 9 Immunohistochemistry of two RA samples, the pictures on the left are from a 26 years-old female 
and on the right of a 77 years-old men; a) Anti-OCL which stains osteoblast and mineralized bone in brown 
were osteocalcin is embedded, 20x objective; b) Anti-DKK1 stains osteocytes where DKK1 is produced, 
the black arrow shows osteocytes, 40x objective; c) Anti-SOST stains osteocytes where sclerostin is 
produced, black arrow shows osteocytes. 40x objective. 
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Rat model of arthritis 
Nine AIA rats were used and as controls 12 healthy Wistar rats were used.  
The inﬂammatory score, ankle perimeter and body weight were measured during the 
study period every other day. At the time of sacrifice vertebrae and long bones, such as 
femur and tibia, were collected for histological evaluation, RNA extraction and three 
point bending test. Blood samples were collected by cardiac puncture for bone turnover 
markers assessment. 
 
Clinical assessment 
Throughout disease duration, the inflammatory score, weight and ankle perimeter 
were access in order to observe the physical effect of arthritis. The inflammatory score 
is significantly increased in the arthritic rats when compared to the healthy ones 
(p<0.001, Fig.10) and reaches a plateau at days 19-20 of disease. Before day 10 post 
induction there were no differences in weight between the two groups (Fig 10). 
However, after day 10, the weight of the arthritic group starts to decrease with 
statistically significantly differences after 14th day of disease. The ankle perimeter of the 
healthy group has a mean of 2 centimetres during the 22 days of the study, while in the 
arthritic group the perimeter increases significantly after the 12th day post disease 
induction (Fig.10). 
 
 
Figure 10 Inflammatory score, weigh and ankle perimeter oh healthy and arthritic rats during the 22 days 
of experiment. Inflammatory score of healthy and arthritic rats during the 22 days of the experiment 
showing a marked increase at day 8 and a plateau at days 19-20. Weight of arthritic rats decreases after 
day 10. Ankle perimeter of arthritic rats increases after day 12. Each point represents the mean of the 
group for each day; *p<0.05;***p<0.001 
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Bone turnover markers 
To access bone turnover, serum levels of CTX-I and P1NP were determined. The 
bone resorption marker CTX-I was significantly higher on the arthritic group (p=0.003) 
but no differences were found in P1NP levels, although it was increased in the arthritic 
rats (Fig.11). CTX-I/P1NP ratio was not significant different between the healthy and 
arthritic rats. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Histomorphometry 
In order to look at the bone microstructure and organization, parameters were 
evaluated by histomorphometry of the 4th lumbar vertebra at day 22 post-disease 
induction. Bone volume (BV/TV) was significantly decreased in the arthritic rats 
(p<0.0001) while trabecular separation (Tb.Sp) is significantly increased (p=0.009; 
Fig.12). Trabecular thickness (Tb.Th) although it is slightly decreased in arthritic rats, 
showed no difference between the groups. 
 
 
 
 
 
Figure 11 CTX-I and P1NP serum concentrations measured in rat serum 22 days after arthritis 
induction and the CTX-I/P1NP ratio. Lines represent median and interquartile range (10-90); 
**p<0.01; CTX-I - C-terminal cross-link telopeptide of type I collagen; P1NP - N-propeptide of type 
I collagen 
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Energy-dispersive X-ray spectroscopy 
Hydroxyapatite (Ca5(PO4)3(OH)) crystals are formed by calcium and phosphorus, so 
it is important to quantify their proportion on bone. Both calcium and phosphorous are 
significantly reduced in arthritic rats (p=0.041 and p=0.031, respectively; Fig.13 
compared to the control group). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three-point bending 
In order to determine the mechanical bone behaviour under a loading force a three-
point bending test was performed. Yield stress is a measure of elasticity and the 
ultimate stress is the energy at which the first microfracture occurs. Both yield stress 
Figure 12 Comparison of BV/TV, Tb.Th and Tb.Sp between healthy and arthritic groups 22 days after 
disease induction; **p<0.01; ***p<0.001. Lines represent median and interquartile range (10-90). 
BV/TV – Bone volume; Tb.Th - Trabecular thickness; Tb.Sp - Trabecular separation 
Figure 13 Calcium (Ca) and Phosphorus (P) proportion on bone of healthy and arthritic groups 22 days 
after disease induction; Lines represent median and interquartile range (10-90); *p<0.05 
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and ultimate stress, were significantly decreased in arthritic femurs (p=0.005 and 
p=0.026 respectively; Fig.14).  
 
 
Figure 14 Bone mechanical properties (yield stress and ultimate stress) were assessed in healthy and 
arthritic groups; Lines represent median and interquartile range (10-90) *p<0.05, **p<0.01 
 
 
Gene expression  
For the animal model of arthritis we studied osteoblast and osteoclast specific 
genes, as well as some involved in the Wnt signalling pathway in bone samples from 
both groups. When comparing healthy and arthritic rats we found that OPG levels are 
decreased in the arthritic animals as is RANKL, CTSK and LRP6 expression. However, 
no significant differences in any of the studied genes were found (Table 7). 
 
Table 7 Gene expression in bone from healthy and arthritic rats 
 
Healthy (n=12) Arthritic (n=9) P-value 
OCN 60.01 [31.31-147.3] 78.18 [51.23-102.0] 0.80 
RANKL 1.18 [0.47-11.56] 0.86 [0.31-3.12] 0.448 
OPG 75854 [35765-136176] 59556 [29432-77259] 0.279 
RANKL/OPG 1.29x10
-5 
[0.53x10
-5
-4.82x10
-5
] 1.23x10
-5 
[0.34x10
-5
-8.49x10
-5
] 0.814 
CTSK 269.2 [115.8-382.6] 92.51 [25.49-329.1] 0.105 
WNT10B 2.12 [1.51-4.35] 2.21 [0.62-8.51] 0.654 
LRP6 1.29 [0.87-1.76] 0.46 [0.27-1.29] 0.052 
WIF1 0.91 [0.60-1.16] 0.77 [0.24-1.54] 0.954 
Values represent median [interquartile range 25-75]; OCN – Osteocalcin; OPG – Osteoprotegerin; RANKL -  
receptor activator of nuclear factor kappa B ligand; CTSK – Cathepsin K; LRP6 - density lipoprotein receptor-
related protein 6; WNT10B - WNT10B Wingless-type MMTV integration site family, member 10B; WIF1 - Wnt 
inhibitory factor 1 
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Discussion 
 
The aim of this study was to analyse the effect of rheumatoid arthritis in the bone 
quality and microstructure level and also osteoblast and Wnt-related gene expression. 
For this work, we recruit RA patients with active disease (DAS18 3V Hospital de 
Santa Maria). RA patients had a mean age of 65 years with mean disease duration of 
4.74 years. Our RA population was composed mostly by women (83%), which is in 
accordance with Alamanos' epidemiology study of RA prevalence in the female gender. 
Sixty percent of RA patients were positive for anti-CCP, a specific and early marker of 
RA and around 55% were positive for rheumatoid factor68,69. Around 70% of RA 
patients were under methotrexate, a commonly used disease-modifying anti-rheumatic 
drug (DMARD)70 and all RA patients were under corticosteroid therapy. As controls, 
two groups were used, patients with osteoporosis and patients with osteoarthritis. 
To complement the study of the influence of inflammation on Wnt pathway on bone, 
we used Wistar rats with adjuvant-induced arthritis as a model of arthritis and we 
studied bone microstructure, bone turnover ratio, mechanical properties and gene 
expression. 
 
Humans – RA and AO patients 
There were no differences between RA and OA patients in sex and age, but unlike 
RA patients, OA patients were not under corticosteroids. 
We first wanted to adress bone quality parameters differences between RA and OA 
patients. Our results show no difference in serum bone turnover markers between RA 
and OA patients which is in accordance with Wislowska et al. who found no differences 
on serum concentrations of formation and resorption markers between RA and OA 
patients71. 
When comparing RA and OA patients' bone mechanical properties we found a slight 
decrease in Young's modulus but no statistical differences were found. Brown et al. 
showed that although there were biomechanical differences between the superior and 
inferior region of a femoral head in compressive modulus and yield strength, when they 
compared an OA femoral head with femoral heads with no features of OA, no 
differences were found72. Rodrigues et al. found that when patients with fragility 
fractures were compared with patients with osteoarthritis, the first have lower Young's 
modulus, yield stress and energy until failure73. Then in 2012, Rodrigues and co-
workers showed that stiffness (Young's modulus) was significantly lower in patients 
with hip fractures comparing with osteoarthritis patients, suggesting that OA patients 
have better mechanical properties than patients with low BMD and fragility fractures 
although in our results we didn’t detected differences between the two groups.  
At gene expression level, there was a tendency for increased expression of 
COL1A1, OPG, RANKL, OSX and LRP6 genes, and decreased expression of SOST 
and WNT10B in RA patients when compared with OA patients. However, none of these 
results were statistically significant. To the best of our knowledge there are no previous 
works comparing trabecular gene bone expression of SEMA 3A, WNT10B, LRP5/6, 
SFRP1, DKK1/2 or WIF1 between RA and OA patients. RANKL and OPG are pivotal 
molecules in the regulation of bone turnover. Xu et al. showed that serum RANKL, 
serum OPG and the calculated ratio were higher in RA than in healthy controls, which 
is in accordance with the role of RANKL/OPG on bone erosions and joint destruction74. 
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Kotake and co-workers found that serum RANKL and the ratio RANKL/OPG were 
significantly higher in RA patients, while serum OPG was lower when compared to OA 
samples75. In our work, we found that both RANKL and OPG expression was higher in 
RA patients, although they did not reach statistical difference.  
OSX and WNT10B are transcription factors essential for osteoblast differentiation 
from mesenchymal stem cells. In this work, we found that OSX and WNT10B 
expression was increased in RA patients when compared to OA samples, although 
these results did not reach statistical significance. In accordance, it was previously 
shown that OSX expression is higher in cultured adipose-derived mesenchymal stem 
cells (ASCs) from RA than OA patients76. Imai et al (2006) showed that WNT10B was 
highly expressed in lining cells and fibroblasts of RA patients when compared with OA 
and these results were confirmed by immunohistochemistry77.  
SFRP1 and SOST are inhibitors of the canonical wnt pathway and, therefore, 
inhibitors of osteoblast differentiation and, consequently, of bone formation. In 
accordance with our results, Ijiri et al (2002) did not found differences in SFRP1 gene 
expression between RA and OA fibroblast-like cells78. We also found a slight increase 
in SOST expression in RA patients when compared to OA samples. By 
immunohistochemistry, Appel et al. found that sclerostin expression by osteocytes on 
joints was slightly higher in RA patients when compared with ankylosis spondylitis, OA 
patients and controls. Comparing directly OA with RA patients, they found that the last 
group had higher expression of sclerostin79.  
One of the limitations of this study is the sample size, which might not be enough to 
detect differences between the two groups. Moreover, we were unable to access OA 
patients BMD which might be of help when interpreting the data and we lack a true 
control group without inflammation or any metabolic bone disease. 
Overall, when comparing RA with OA bone we observed no differences in bone 
mechanics, serum turnover markers or bone gene expression. 
 
 
Humans – RA and OP patients 
Both our RA and OP cohorts of patients have osteoporotic T-scores (lower than -
2.5) and low BMD (less than 0.7 g/cm2)80. Accordingly, we found no differences on 
either serum P1NP or CTX-I levels, neither on the ratio CTX-I/P1NP when comparing 
RA and OP patients. These results are in accordance with previous studies that didn’t 
found statistical differences between serum levels of these biomarkers between RA 
and OP patients51. Moreover, Xu et al. showed that both serum markers levels CTX-I 
and P1NP were higher in osteoporotic group when compared with the healthy 
controls81. Since RA and OP are characterized by loss of bone mass loss, we expected 
both groups to have similar levels of bone turnover markers. We also found no 
differences in bone biomechanical properties (Yield stress, Young’s modulus and 
energy until failure), which is in accordance with previous studies who also didn't found 
any differences in any of these parameters81.  
When comparing gene expression, our results show a significant decrease on the 
expression of osteoblast genes COL1A1, RANKL and also on some Wnt signalling 
pathway genes as WNT10B, SFRP1 and DKK1 in RA patients when compared with 
OP patients. In accordance with our results, Patsch et al. showed that RANKL gene 
expression was higher in the group of men with idiopathic osteoporosis when 
compared with healthy controls82. Moreover it was shown that the RANKL/OPG ratio is 
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significantly higher in the bone marrow of patients with fractures as opposed to OA 
patients, but they did not find differences when compared gene expression in bone 
samples from the same groups83. Previous studies also showed that although serum 
RANKL was significantly decreased in RA when compared with OP patients  no 
difference was found at the gene expression level51. Regarding the Wnt pathway 
players, Patsch and co-workers found that WNT10B expression was significantly 
higher in the group with idiopathic osteoporosis when compared with the healthy 
controls82. Moreover, it was described by Dovjak et al that DKK1 serum levels were 
increased in patients with hip fractures when compared with young controls84. D’Amelio 
et al shows that the expression of DKK1 was higher in the fractured patients, both in 
bone and bone marrow when compared to OA samples83. In contrast with our results, a 
previous study has shown no differences on serum DKK1 levels, but DKK1 gene 
expression was significantly higher in RA patients when compared to OP bone 
samples51. No studies describing SEMA3A, WNT10B, LRP5/6, SFRP1, DKK1/2 or 
WIF1 gene expression in human trabecular bone were found.  
OP patients underwent hip replacement surgery due to fragility fracture, which might 
influence the expression of some of the genes studied. Therefore, we evaluated the 
expression of the same genes we compared between RA and OP patients in the post-
fracture period. Comparing OP patients with different time between fracture and 
surgery, we found no differences in osteoblast’s gene expression, which is in according 
with a previous study67. 
Again, this work has some limitations, namely the small sample size and the lack a 
true control group. Moreover, we studied gene expression at the bone 
microenvironment level including bone, bone marrow, fat and vessels making the 
results hard to interpret since some of the genes studied are not only expressed by 
osteoblasts but also by other cells in the surrounding environment. 
Taken together, our results suggest that OP and RA patients have similar bone 
fragility but while OP is characterized by increased bone resorption85, we show here 
that in RA bone the wnt pathway is downregulated, which might negatively influence 
bone formation and contribute to bone fragility. 
 
Animal model 
As expected, during the 22 post-induction days the inflammatory score of arthritic 
rats increases and they lose weight suggesting that the disease has a systemic effect. 
These symptoms are confirmed by Cai et al. (2006) who compared the effect of 
adjuvant-induced arthritis on Sprague-Dawley and Lewis rats86. 
When studying bone turnover, we found a high level of the bone resorption marker 
CTX-I in arthritic rats and a tendency to increase the bone formation marker P1NP. In 
accordance with our results, previous studies have described that in AIA model there is 
increased bone resorption by osteoclasts15,14. Moreover, Shopf and Noguchi, in 
different studies, described that collagen oligomeric matrix protein and CTX-I have 
higher levels in AIA arthritis when compared to the control group15,87. Using 
histomorphometry, we observed that arthritic rats have less bone volume with higher 
separation between trabeculae and a tendency for thinner trabeculae, which is in 
accordance with what has been described by Nanjundaiah et al.88. In accordance with 
our results, Osterman et al. performed histomorphometry in femoral metaphysic and 
found lower percent total bone area, trabecular thickness and trabecular number in the 
arthritic group when compared with healthy one, while trabecular separation was 
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significantly higher89. Noguchi et al. performed microCT of trabecular bone in 
calcaneous and found that BV/TV was significantly decreased in arthritic rats 
comparing to healthy ones87.  
To the best of our knowledge, there are no publications measuring arthritic rat bone 
mineral content with energy dispersive X-ray spectroscopy. When we compared the 
mineral content of healthy and arthritic bone, our results shown that arthritic rats have 
less calcium and phosphorus than healthy bones, which might indicate that there is no 
sufficient mineral for this bone to have a normal behaviour on mechanical tests. This 
different can be attributed to low calcium and phosphorus serum content or to poor 
osteoblast activity. Moreover, in accordance with these observations we found that the 
yield stress and ultimate stress of arthritic rats is significant lower than in healthy 
animals. Other studies in a mouse model of arthritis found that arthritic bone has 
significant worse mechanical properties with three-point bending test of femurs63.   
Regarding gene expression, no differences were found between arthritic and healthy 
rat samples. Several studies assessed the expression of bone-related genes on rat 
bone with contradictory results. Kishimoto et al found that in a collagen-induced arthritis 
model, that CTSK and RANKL expression was higher in arthritic when compared with 
the healthy rats, while OPG expression was decreased90. Ho et al. found that arthritic 
rats have higher levels of circulating RANKL, while OPG levels were similar between 
arthritic with healthy rats, and at gene expression level, both RANKL and OPG were 
higher in arthritic rats, as well as the ratio RANKL/OPG91. Engdahl et al. showed that 
RANKL expression was reduced in arthritic mice in synovial tissue, bone marrow and 
trabecular bone and OPG expression was significantly reduced in synovial, but not on 
bone marrow and trabecular bone when compared to healthy controls92. To the best of 
our knowledge no studies evaluated bone gene expression of OCL, WNT10B, LRP6 or 
WIF1. 
The AIA model used in this work is a widely used model to study not only the 
physiopathology of arthritis but also to test the effect of drugs on the development of 
the disease. However, this model has an acute, rather than chronic, inflammation that 
resolves spontaneously over time. Although we believe that the effect of this resolution 
of inflammation might not be observed immediately on bone quality parameters, it may 
explain the lack of differences on gene expression between groups. Moreover, gene 
expression was performed in the bone microenvironment, rather than on bone and 
bone marrow separately, as was published by several works.   
In summary, arthritic rats showed higher bone resorption, lower bone volume and 
trabecular separation and less mineral content, leading to worst mechanical properties. 
No differences were found at the gene expression level, which we believe to be a 
limitation of the model.  
 
As conclusion, this thesis shows that RA bone fragility might be driven by osteoblast 
function deterioration, rather than by excessive bone resorption, through 
downregulation of the canonical Wnt pathway. More studies are needed to identify the 
mechanisms by which RA downregulates the Wnt canonical pathway. 
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Anex 1 
 
Human primers 
Gene 
symbol 
Gene name 
GenBank 
number 
Product 
length 
(bp) 
Primer sequences 
PMM1 
Phosphomannomutase 1 
(Housekeeping) 
NM_002676 96 
F:GAATGGCATGCTGAACATCTC 
R:TCCCGGATCTTCTCTTTCTTG 
ALP Bone Alkaline phosphatase  NM_000478.3 74 
F:GCGCAGGATTGGAACATC 
R:CCCAAGACCTGCTTTATCCC 
COL1A1 Collagen type I alpha 1 NM_00085313.3 129 
F:ACGAAGACATCCCACCAATC 
R:AGATCACGTCATCGCACAAC 
DKK1 Dickkopf protein 1 NM_012242.2 120 
F: CAGGCGTGCAAATCTGTCT 
R: AATGATTTTGATCAGAAGACACACATA 
DKK2 Dickkopf protein 2 NM_014421 72 
F: GGCAGTAAGAAGGGCAAAAA 
R: CCTCCCAACTTCTTCACACTCCT 
LRP5 
Low-Density Lipoprotein 
Receptor-Related Protein 5 
NM_002335.2 60 
F: GAACATCAAGCGAGCCAAG 
R: TGGCTCAGAGAGGTCAAAACA 
LRP6 
Low-Density Lipoprotein 
Receptor-Related Protein 6 
NM_002336.2 64 
F: ATCCGAAAGGCACAAGAAGA 
R: GACTCGGAACTGAGCTCACAA 
OCN Osteocalcin NM_199173 198 
F:CCAGGCAGGTGCGAAG 
R:TCAGCCAACTCGTCACAGTC 
OPG Osteoprotegerin NM_002546 185 
F:CGCTCGTGTTTCTGGACAT 
R:GTAGTGGTCAGGGCAAGGG 
OSX Osterix NM_152860.1 91 
F:CCCTGCTTGAGGAGGAAGTT 
R:GTAAAGGGGGCTGGATAAGC 
RANKL 
Receptor activator of 
nuclear factor kappa-B 
ligand 
NM_003701 116 
F:AGAGAAAGCGATGGTGGATG 
R:TATGGGAACCAGATGGGATG 
RUNX2 
Runt-related transcription 
factor 2 
NM_004348 193 
F:CGGAATGCCTCTGCTGTTA 
R:TCTGTCTGTGCCTTCTGGGT 
SEMA 3A Semaphorin 3A NM_006080.2 65 
F:TGAAATTGGACATCATCCTGAG 
R:GGCCGTTTTCAAAATGTGAG 
SFRP1 
Secreted frizzled-related 
protein 1 
NM_003012.4 75 
F:GCTGGAGCACGAGACCAT 
R:TGGCAGTTCTTGTTGAGCA 
SOST Sclerostin NM_025237 196 
F:AGACCAAAGACGTGTCCGAG 
R:GGGATGCAGCGGAAGTC 
WIF1 WNT inhibitory factor 1 NM_007191 72 
F: CCAGGGAGACCTCTGTTCAA 
R: TTGGGTTCATGGCAGGTT 
WNT10B 
Wingless-type MMTV 
integration site family 
member 10B 
NM_003394 107 
F: GCGAATCCACAACAACAGG 
R: TCCAGCATGTCTTGAACTGG 
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Rat primers  
 
Gene symbol Gene name 
GenBank 
number 
Product 
length 
(bp) 
Primer sequences 
RPS29 
Ribossomal protein S29 
(Housekeeping) 
NM_012876.1 109 
F:TCCTTTTTCCTCCTTGGGCG 
R:TTAGAGCAGACGCGGCAAGA 
CTSK Cathepsin K NM_031560.2 73 
F: GGGAGACATGACCAGCGAAG 
R: ACTGAAGGAACGCGAAGGTG 
LRP6 
Low density lipoprotein 
receptor-related proein 6 
NM_001107892.1 145 
F:GCAAAGATGGTGCCACTGAA 
R:TCCACGGGGTCGTAGTCTAT 
OCN Osteocalcin NM_013414.1 91 
F: TCAACAATGGACTTGGAGCCC 
R: AGCTCGTCACAATTGGGGTT 
OPG Osteoprotegerin NM_012870.2 108 
F: CTCACTTGGCCTCCTGCTAA 
R: TCGCACAGGGTGACATCTAT 
RANKL 
Receptor activator of nuclear 
factor kappa-B ligand 
NM_057149.1 98 
F: CGAGCGCAGATGGATCCTA 
R:AGTGCTTCTGTGTCTTCGC 
WIF-1 WNT inhibitory factor 1 NM_053738.1 95 
F: GGCATCAGTTGTTCAAGTTGGTTTC 
R: TGCCTTCAGAATTCATGACAATCAC 
WNT10B 
Wingless-type MMTV 
integration site family 
member 10B 
NM_001108111.1 102 
F: GTTCAGTCGGGCTCTAAGCA 
R:TTACTCAAGCCGGACAGGGT 
 
 
